One To Watch
Blueprint Medicines
A global precision therapy company that develops therapies for people with cancer and blood disorders.
The US biotech company's assets include avapritinib, BLU-554 and BLU-667, selective investigational kinase medicines developed that have demonstrated clinical proof-of-concept in genomically defined subsets of patients with cancer.
Latest Blueprint Medicines News
Today's issue
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze